BR112019016635A2 - aminotriazolopiridinas como inibidores da cinase - Google Patents

aminotriazolopiridinas como inibidores da cinase Download PDF

Info

Publication number
BR112019016635A2
BR112019016635A2 BR112019016635A BR112019016635A BR112019016635A2 BR 112019016635 A2 BR112019016635 A2 BR 112019016635A2 BR 112019016635 A BR112019016635 A BR 112019016635A BR 112019016635 A BR112019016635 A BR 112019016635A BR 112019016635 A2 BR112019016635 A2 BR 112019016635A2
Authority
BR
Brazil
Prior art keywords
aminotriazolopyridines
kinase inhibitors
diastereomers
prodrugs
stereoisomers
Prior art date
Application number
BR112019016635A
Other languages
English (en)
Portuguese (pt)
Inventor
Guo Junqing
C. Hart Amy
E. Macor John
E. Mertzman Michael
J. Pitts William
H. Spergel Steven
Hunter Watterson Scott
Andappan Murugaiah Subbaiah Murugaiah
Chen Jie
Diane Dzierba Carolyn
Luo Guanglin
Shi Jianliang
Sit Sing-Yuen
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BR112019016635A2 publication Critical patent/BR112019016635A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112019016635A 2017-02-13 2018-02-12 aminotriazolopiridinas como inibidores da cinase BR112019016635A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112019016635A2 true BR112019016635A2 (pt) 2020-04-07

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019016635A BR112019016635A2 (pt) 2017-02-13 2018-02-12 aminotriazolopiridinas como inibidores da cinase

Country Status (25)

Country Link
US (3) US10913738B2 (enExample)
EP (1) EP3580220B1 (enExample)
JP (1) JP7097373B2 (enExample)
KR (1) KR102549952B1 (enExample)
CN (1) CN110520423B (enExample)
AU (1) AU2018217488B2 (enExample)
BR (1) BR112019016635A2 (enExample)
CA (1) CA3053484A1 (enExample)
CY (1) CY1124978T1 (enExample)
DK (1) DK3580220T3 (enExample)
EA (1) EA039808B1 (enExample)
ES (1) ES2902676T3 (enExample)
HR (1) HRP20212000T1 (enExample)
HU (1) HUE057801T2 (enExample)
IL (1) IL268614B (enExample)
LT (1) LT3580220T (enExample)
MA (1) MA47460A (enExample)
MX (1) MX378515B (enExample)
PL (1) PL3580220T3 (enExample)
PT (1) PT3580220T (enExample)
RS (1) RS62801B1 (enExample)
SG (1) SG11201907335UA (enExample)
SI (1) SI3580220T1 (enExample)
SM (1) SMT202200001T1 (enExample)
WO (1) WO2018148626A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148626A1 (en) * 2017-02-13 2018-08-16 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
LT3704118T (lt) 2017-10-30 2022-02-25 Bristol-Myers Squibb Company Aminoimidazopiridazinai, kaip kinazės inhibitoriai
EA202091777A1 (ru) 2018-01-26 2020-10-14 Бристол-Маерс Сквибб Компани Аминопирролотриазины в качестве ингибиторов киназы
SG11202100137TA (en) * 2018-07-09 2021-02-25 Lieber Institute Inc PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
US12234221B2 (en) 2018-07-09 2025-02-25 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NAV1.8
AU2019339355A1 (en) * 2018-09-13 2021-05-13 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
JP7599411B2 (ja) 2018-09-13 2024-12-13 ブリストル-マイヤーズ スクイブ カンパニー 受容体相互作用タンパク質キナーゼ1阻害剤(ripk1)としての1h-インダゾールカルボキサミド
TWI724753B (zh) * 2019-01-25 2021-04-11 大陸商北京賽特明強醫藥科技有限公司 醯胺基橋連雜環類化合物、及其組合物與應用
CN113508109B (zh) * 2019-03-22 2023-02-10 劲方医药科技(上海)有限公司 取代的杂环酰胺类化合物,其制法与医药上的用途
KR20220079593A (ko) 2019-10-03 2022-06-13 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
MX2022009898A (es) * 2020-02-13 2022-08-25 Genfleet Therapeutics Shanghai Inc Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322A (zh) * 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
KR102707109B1 (ko) 2021-08-10 2024-09-20 애브비 인코포레이티드 니코틴아미드 ripk1 억제제
WO2023174374A1 (zh) 2022-03-16 2023-09-21 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用
CN114989079B (zh) * 2022-06-21 2023-06-23 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
AR133939A1 (es) * 2023-09-27 2025-11-19 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de cinasa
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004702A1 (en) * 2004-06-25 2006-01-12 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CA2706578A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
JP5589003B2 (ja) 2009-02-04 2014-09-10 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 脂質障害のような代謝疾患の処置のために有用な[1,3]オキサジン−2−オンの誘導体
EP2897949B1 (en) 2012-09-18 2018-01-10 Bristol-Myers Squibb Company Iap antagonists
CA2914668A1 (en) 2013-06-10 2014-12-18 Volker Schulze Novel compounds for the treatment of cancer
RU2017109122A (ru) * 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
EP3372604B1 (en) 2015-11-05 2021-12-01 Sumitomo Chemical Company, Limited Condensed heterocyclic compound
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
WO2018148626A1 (en) * 2017-02-13 2018-08-16 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
LT3704118T (lt) 2017-10-30 2022-02-25 Bristol-Myers Squibb Company Aminoimidazopiridazinai, kaip kinazės inhibitoriai
EA202091777A1 (ru) 2018-01-26 2020-10-14 Бристол-Маерс Сквибб Компани Аминопирролотриазины в качестве ингибиторов киназы
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
MX378515B (es) 2025-03-11
HUE057801T2 (hu) 2022-06-28
SMT202200001T1 (it) 2022-03-21
US12157733B2 (en) 2024-12-03
US20250074909A1 (en) 2025-03-06
KR20190117006A (ko) 2019-10-15
JP7097373B2 (ja) 2022-07-07
MA47460A (fr) 2019-12-18
WO2018148626A1 (en) 2018-08-16
DK3580220T3 (da) 2022-01-10
KR102549952B1 (ko) 2023-06-29
US10913738B2 (en) 2021-02-09
AU2018217488B2 (en) 2021-09-23
AU2018217488A1 (en) 2019-10-03
SI3580220T1 (sl) 2022-01-31
IL268614B (en) 2021-12-01
MX2019009555A (es) 2019-10-02
CY1124978T1 (el) 2023-01-05
IL268614A (en) 2019-10-31
CA3053484A1 (en) 2018-08-16
SG11201907335UA (en) 2019-09-27
PL3580220T3 (pl) 2022-02-07
CN110520423A (zh) 2019-11-29
JP2020507582A (ja) 2020-03-12
US20220315580A1 (en) 2022-10-06
HRP20212000T1 (hr) 2022-04-01
RS62801B1 (sr) 2022-02-28
ES2902676T3 (es) 2022-03-29
PT3580220T (pt) 2022-01-03
EA201991915A1 (ru) 2019-12-30
EA039808B1 (ru) 2022-03-16
CN110520423B (zh) 2022-08-23
US20190389859A1 (en) 2019-12-26
EP3580220A1 (en) 2019-12-18
LT3580220T (lt) 2021-12-27
EP3580220B1 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
BR112019016635A2 (pt) aminotriazolopiridinas como inibidores da cinase
CA3080402A1 (en) Aminoimidazopyridazines as kinase inhibitors
MX2021002617A (es) Indazol carboxamidas como inhibidores de cinasas.
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CL2021002519A1 (es) Compuestos de diazina-amida activos como pesticidas.
DOP2020000249A (es) N-benzisoxazolilo bencenosulfonamidas como inhibidores de kat
UY37537A (es) Derivados de pirazol como inhibidores malt1
MX2022003769A (es) Indazol carboxamidas como inhibidores de cinasas.
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
JOP20190254A1 (ar) مركبات مضادة للأورام
MX382562B (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub).
MX2018012266A (es) Amidas heterociclicas como moduladores de proteinas.
MX373866B (es) Amidas heterocíclicas como inhibidores de cinasas.
MD3319967T2 (ro) Compuşi inhibitori ai căii de semnalizare Notch
EA202190718A1 (ru) Индазолкарбоксамиды в качестве ингибиторов киназ
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
TN2011000274A1 (en) Carbazole carboxamide compounds useful as kinase inhibitors
BR112018013251A2 (pt) compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase
PH12021551317A1 (en) Modulators of trex1
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CO2023004926A2 (es) Compuestos de triazolopiridinilo como inhibidores de quinasas
UY36629A (es) Indazolonas como moduladores de la señalización de tnf
MX2018004979A (es) Compuesto piranodipiridinico.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
WO2019094552A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]